HRP20240906T1 - Agonisti crf2 receptora i njihova primjena u terapiji - Google Patents

Agonisti crf2 receptora i njihova primjena u terapiji Download PDF

Info

Publication number
HRP20240906T1
HRP20240906T1 HRP20240906TT HRP20240906T HRP20240906T1 HR P20240906 T1 HRP20240906 T1 HR P20240906T1 HR P20240906T T HRP20240906T T HR P20240906TT HR P20240906 T HRP20240906 T HR P20240906T HR P20240906 T1 HRP20240906 T1 HR P20240906T1
Authority
HR
Croatia
Prior art keywords
gglu
lysine
aeea
glutamine
glutamate
Prior art date
Application number
HRP20240906TT
Other languages
English (en)
Croatian (hr)
Inventor
Stephane Illiano
Laurence LUCATS
Laetitia LEDEIN
Philippe Beauverger
Philip Janiak
Marie-Laure Ozoux
Nis Halland
Ziyu Li
Ralf Elvert
Andreas Evers
Elisabetta Bianchi
Alessia Santoprete
Daniela ROVERSI
Martina TRIPEPI
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of HRP20240906T1 publication Critical patent/HRP20240906T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20240906TT 2020-08-19 2021-08-18 Agonisti crf2 receptora i njihova primjena u terapiji HRP20240906T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20315387 2020-08-19
PCT/EP2021/072923 WO2022038179A1 (en) 2020-08-19 2021-08-18 Crf2 receptor agonists and their use in therapy
EP21777954.5A EP4199946B1 (en) 2020-08-19 2021-08-18 Crf2 receptor agonists and their use in therapy

Publications (1)

Publication Number Publication Date
HRP20240906T1 true HRP20240906T1 (hr) 2024-10-11

Family

ID=72615799

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240906TT HRP20240906T1 (hr) 2020-08-19 2021-08-18 Agonisti crf2 receptora i njihova primjena u terapiji

Country Status (16)

Country Link
US (1) US20250243255A1 (enExample)
EP (2) EP4199946B1 (enExample)
JP (1) JP7832927B2 (enExample)
KR (1) KR20230051583A (enExample)
CN (1) CN116472053A (enExample)
AU (1) AU2021328673A1 (enExample)
CA (1) CA3192032A1 (enExample)
ES (1) ES2988026T3 (enExample)
HR (1) HRP20240906T1 (enExample)
HU (1) HUE066991T2 (enExample)
IL (1) IL300464A (enExample)
IS (1) IS3063B (enExample)
MX (1) MX2023002087A (enExample)
PL (1) PL4199946T3 (enExample)
WO (1) WO2022038179A1 (enExample)
ZA (1) ZA202301784B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
EP4234574A1 (en) * 2022-02-23 2023-08-30 Corteria Pharmaceuticals Crf2 receptor agonists and their use in therapy
WO2025104264A1 (en) 2023-11-17 2025-05-22 Gubra A/S Hcrhr2 selective polypeptides
TW202544027A (zh) * 2024-04-19 2025-11-16 美商紐羅克里生物科學有限公司 促皮質素釋放因子受體２（ｃｒｆｒ２）促效劑
WO2025230248A1 (ko) * 2024-04-30 2025-11-06 한미약품 주식회사 Crf2 수용체 작용제와 그 아실화 결합체의 용도
WO2026064495A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026064486A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
CN104356224A (zh) 2014-10-24 2015-02-18 杭州阿德莱诺泰制药技术有限公司 一种制备萨摩鲁泰的方法
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy

Also Published As

Publication number Publication date
KR20230051583A (ko) 2023-04-18
EP4199946A1 (en) 2023-06-28
ZA202301784B (en) 2024-01-31
EP4435001A3 (en) 2024-10-09
WO2022038179A1 (en) 2022-02-24
PL4199946T3 (pl) 2024-08-19
IL300464A (en) 2023-04-01
HUE066991T2 (hu) 2024-09-28
MX2023002087A (es) 2023-03-23
AU2021328673A1 (en) 2023-03-30
JP2023541798A (ja) 2023-10-04
CN116472053A (zh) 2023-07-21
JP7832927B2 (ja) 2026-03-18
EP4199946C0 (en) 2024-06-05
IS3063B (is) 2025-06-15
US20250243255A1 (en) 2025-07-31
EP4435001A2 (en) 2024-09-25
ES2988026T3 (es) 2024-11-19
CA3192032A1 (en) 2022-02-24
EP4199946B1 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
HRP20240906T1 (hr) Agonisti crf2 receptora i njihova primjena u terapiji
HRP20140586T1 (hr) Peptidi za lijeäśenje beta-amiloidoze
JP2023541798A5 (enExample)
JP2010529957A5 (enExample)
RU2013154066A (ru) Новые производные оксинтомодулина и содержащая их фармацевтическая композиция для лечения ожирения
RU2010101232A (ru) Производное инсулинотропного пептида, содержащее модифицированную n-концевую аминокислоту
RU2012101274A (ru) Соединения глюкагона, активные в отношении рецептора gip
JP2007500747A5 (enExample)
JP2006514104A5 (enExample)
HRP20160594T1 (hr) Uporaba mimotopa od alfa-sinuklein epitopa za liječenje bolesti s lewyjevim tijelima
JP2025508820A5 (enExample)
JP2023551122A5 (enExample)
JP2007535910A5 (enExample)
JP2018505153A5 (enExample)
SI3191504T1 (en) Ezrine-derived peptides and their pharmaceutical compositions
RU2010128602A (ru) Циклический белок, не содержащий остатков цистеина
EP2462155B1 (en) Novel antipathogenic peptides
JP2021531246A5 (enExample)
AU2017350304B2 (en) Influenza virus neutralizing compounds
AU2016261299B2 (en) Influenza virus neutralizing peptidomimetic compounds
RU2024126937A (ru) Агонисты рецепторов crf2 и их применение в терапии
JP2024504136A5 (enExample)
JP2005126360A (ja) 新規なポリペプチドで構成されたコラゲナーゼ阻害剤
JP2023510019A5 (enExample)
NZ822560A (en) Novel triple glp-1/gip/glucagon receptor agonist and a pharmaceutical composition for preventing or treating obesity comprising the same